- $2.51bn
- $3.24bn
- $822.45m
- 89
- 50
- 13
- 49
Annual income statement for Neogen, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2019 May 31st | 2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 414 | 418 | 468 | 527 | 822 |
| Cost of Revenue | |||||
| Gross Profit | 192 | 196 | 215 | 243 | 406 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 345 | 351 | 394 | 469 | 785 |
| Operating Profit | 68.8 | 67.5 | 74.2 | 58.6 | 37.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 73 | 72.3 | 75.3 | 60.2 | -22 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 60.2 | 59.5 | 60.9 | 48.3 | -22.9 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 60.2 | 59.5 | 60.9 | 48.3 | -22.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 60.2 | 59.5 | 60.9 | 48.3 | -22.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.569 | 0.563 | 0.568 | 0.447 | 0.115 |